JP2006518197A5 - - Google Patents

Download PDF

Info

Publication number
JP2006518197A5
JP2006518197A5 JP2006501525A JP2006501525A JP2006518197A5 JP 2006518197 A5 JP2006518197 A5 JP 2006518197A5 JP 2006501525 A JP2006501525 A JP 2006501525A JP 2006501525 A JP2006501525 A JP 2006501525A JP 2006518197 A5 JP2006518197 A5 JP 2006518197A5
Authority
JP
Japan
Prior art keywords
compound
compound according
lna
ras
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006501525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518197A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/DK2004/000097 external-priority patent/WO2004069992A2/en
Publication of JP2006518197A publication Critical patent/JP2006518197A/ja
Publication of JP2006518197A5 publication Critical patent/JP2006518197A5/ja
Withdrawn legal-status Critical Current

Links

JP2006501525A 2003-02-10 2004-02-10 ラス発現の改変のためのオリゴマー化合物 Withdrawn JP2006518197A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200300184 2003-02-10
DKPA200301539 2003-10-20
PCT/DK2004/000097 WO2004069992A2 (en) 2003-02-10 2004-02-10 Oligomeric compounds for the modulation of ras expression

Publications (2)

Publication Number Publication Date
JP2006518197A JP2006518197A (ja) 2006-08-10
JP2006518197A5 true JP2006518197A5 (https=) 2007-03-22

Family

ID=32852146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006501525A Withdrawn JP2006518197A (ja) 2003-02-10 2004-02-10 ラス発現の改変のためのオリゴマー化合物

Country Status (6)

Country Link
US (2) US20040248840A1 (https=)
EP (1) EP1592795A2 (https=)
JP (1) JP2006518197A (https=)
AU (1) AU2004209599A1 (https=)
CA (1) CA2515644A1 (https=)
WO (1) WO2004069992A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003085110A2 (en) 2002-04-05 2003-10-16 Santaris Pharma A/S Oligomeric compounds for the modulation hif-1alpha expression
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20040241717A1 (en) * 2003-02-10 2004-12-02 Santaris Pharma A/S Oligomeric compounds for the modulation of thioredoxin expression
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
KR20070095882A (ko) * 2004-11-09 2007-10-01 산타리스 팔마 에이/에스 Ｌｎａ 올리고뉴클레오티드 및 암의 치료
WO2006105487A1 (en) * 2005-03-31 2006-10-05 Amgen Inc. Method for selectively blocking hemoglobin rna amplification
US20090069263A1 (en) * 2005-12-16 2009-03-12 Damha Masad J 4'-thioarabinonucleotide-containing oligonucleotides, compounds and methods for their preparation and uses thereof
CA2648132C (en) * 2006-04-03 2019-05-28 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
US20100021914A1 (en) * 2006-11-23 2010-01-28 Querdenker Aps Oligonucleotides for modulating target rna activity
EP2001188A1 (en) * 2007-06-08 2008-12-10 F.Hoffmann-La Roche Ag Method for authenticating a medical device and a remote device
AU2008270835A1 (en) * 2007-06-29 2009-01-08 F. Hoffmann-La Roche Ag Device and methods for optimizing communications between a medical device and a remote electronic device
EP2186035B1 (en) * 2007-06-29 2018-12-26 Roche Diabetes Care GmbH Apparatus and method for remotely controlling an ambulatory medical device
DK2548962T3 (en) 2007-09-19 2016-04-11 Applied Biosystems Llc Sirna sequence-independent modification formats to reduce off-target phenotype effects in RNAI and stabilized forms thereof
JP5872162B2 (ja) * 2007-11-26 2016-03-01 エンゾン ファーマシューティカルズ，インコーポレーテッド アンドロゲン受容体を標的化するｌｎａアンタゴニスト
US7863437B2 (en) * 2007-12-03 2011-01-04 Enzon Pharmaceuticals, Inc. RNA antagonist compounds for the modulation of PIK3CA expression
EP2580228B1 (en) 2010-06-08 2016-03-23 Ionis Pharmaceuticals, Inc. Substituted 2'-amino and 2'-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
ES2677070T3 (es) * 2010-10-27 2018-07-27 Curna, Inc. Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
HK1200484A1 (zh) 2011-09-14 2015-08-07 Translate Bio Ma, Inc. 多聚寡核苷酸化合物
JP2015511821A (ja) * 2012-03-12 2015-04-23 ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブＲｏｃｈｅ Ｉｎｎｏｖａｔｉｏｎ Ｃｅｎｔｅｒ Ｃｏｐｅｎｈａｇｅｎ Ａ／Ｓ Ａｔｘｎ３発現の調節のための組成物および方法
CA2873766A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating atp2a2 expression
JP2015523854A (ja) 2012-05-16 2015-08-20 ラナ セラピューティクス インコーポレイテッド Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
CA2873769A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating hemoglobin gene family expression
US10837014B2 (en) 2012-05-16 2020-11-17 Translate Bio Ma, Inc. Compositions and methods for modulating SMN gene family expression
BR112014028634A2 (pt) 2012-05-16 2017-06-27 Rana Therapeutics Inc composições e métodos para modulação da expressão de utrn
AU2013262709A1 (en) 2012-05-16 2015-01-22 Rana Therapeutics, Inc. Compositions and methods for modulating MECP2 expression
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6429264B2 (ja) * 2013-11-12 2018-11-28 学校法人東京理科大学 ボラノホスフェート化合物、及び核酸オリゴマー
US10266828B2 (en) 2013-12-16 2019-04-23 Syddansk Universitet RAS exon 2 skipping for cancer treatment
WO2016127002A1 (en) * 2015-02-04 2016-08-11 Bristol-Myers Squibb Company Lna oligonucleotides with alternating flanks
EP3254104B1 (en) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Methods of selecting therapeutic molecules
AU2016215155A1 (en) 2015-02-04 2017-08-17 F. Hoffmann-La Roche Ag Tau antisense oligomers and uses thereof
WO2016130943A1 (en) * 2015-02-13 2016-08-18 Rana Therapeutics, Inc. Hybrid oligonucleotides and uses thereof
WO2019046698A1 (en) * 2017-09-01 2019-03-07 Thomas Jefferson University COMPOSITIONS AND METHODS FOR MYC GENE MESSENGER RNA INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US5935779A (en) * 1988-11-03 1999-08-10 Igen International Inc. Methods for improved particle electrochemiluminescence assay
US5962218A (en) * 1988-11-03 1999-10-05 Igen International Inc. Methods and apparatus for improved luminescence assays
AU672175B2 (en) * 1991-06-14 1996-09-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of the ras gene
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US6794499B2 (en) * 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
US20020068709A1 (en) * 1999-12-23 2002-06-06 Henrik Orum Therapeutic uses of LNA-modified oligonucleotides
WO2002097114A2 (en) * 2001-05-29 2002-12-05 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
US20040241717A1 (en) * 2003-02-10 2004-12-02 Santaris Pharma A/S Oligomeric compounds for the modulation of thioredoxin expression

Similar Documents

Publication Publication Date Title
JP2006518197A5 (https=)
JP6626101B2 (ja) ＧａｌＮＡｃホスホラミダイト、その核酸結合体およびそれらの使用
KR101878587B1 (ko) 올리고머 및 올리고머 접합체
US10041074B2 (en) Euchromatic region targeting methods for modulating gene expression
CN109843902B (zh) 用于B型肝炎病毒感染的RNAi剂
CA3004799C (en) Oligonucleotides for inducing paternal ube3a expression
JP7798836B2 (ja) Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子
JP4777777B2 (ja) ｍＲＮＡ前駆体のスプライシングを修飾するＥＮＡ核酸医薬
US10758558B2 (en) Hybrid oligonucleotides and uses thereof
WO2017178656A1 (en) TRITYL-MONO-GalNAc COMPOUNDS AND THEIR USE
CN104755621A (zh) 癌症治疗
JP2010524486A (ja) β−カテニンを調節するためのＲＮＡアンタゴニスト化合物
CN110832077A (zh) 用于抑制α-ENaC表达的RNAi剂及使用方法
CN105247052A (zh) B-细胞cll/淋巴瘤11a(bcl11a)的寡核苷酸调节剂及其用途
KR20190047025A (ko) 변형된 올리고뉴클레오티드 및 사용 방법
WO2016130929A1 (en) Targeting oligonucleotides and uses thereof to modulate gene expression
JP2007533742A5 (ja) 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物
JP2021524277A (ja) Ｒｔｅｌ１発現の調節用のオリゴヌクレオチド
JP2012529279A (ja) 新規の強力な抗ａｐｏｂアンチセンス化合物
US20100249219A1 (en) Short rna antagonist compounds for the modulation of hif-1alpha
JP2004526737A5 (https=)
JP2011505798A (ja) Ｍｃｌ−１を調節するためのＲＮＡアンタゴニスト化合物
EP3568481A1 (en) Antisense oligonucleotides for modulating relb expression
CN115485381A (zh) 以apoc3为靶点的反义核酸
JP7813254B2 (ja) Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド